articleBloodApr 18, 2014GREEN OA

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

PAPhilippe ArmandHTHaesook T. KimBRBrent R. LoganZWZhiwei WangEPEdwin P. Alyea

Dana-Farber Cancer Institute · Medical College of Wisconsin · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able to stratify patients undergoing HCT by disease risk. The Disease Risk Index (DRI) was developed for this purpose. In this study, we analyzed 13,131 patients reported to the Center for International Blood and Marrow Transplant Research who underwent HCT between 2008 and 2010. The DRI stratified patients into 4 groups with 2-year overall survival (OS) ranging from 64% to 24% and was the strongest prognostic factor, regardless of age, conditioning intensity, graft source, or donor type. A randomly selected training subgroup of 9849 patients was used to…

Citation impact

933
total citations
FWCI
25.88
Percentile
100%
References
17
Citations per year

Authors

13

Topics & keywords

Topics
Keywords
  • Transplantation
  • Stem cell
  • Medicine
  • Disease
  • Hematopoietic stem cell transplantation
  • Graft-versus-host disease
  • Oncology
  • Immunology
No related works found for this paper.

Funding